NIH Grant Terminations: New Data Shows Disproportionate Harm to Women and Early-Career Researchers

Hook

A new peer-reviewed study published in the Proceedings of the National Academy of Sciences exposes a sobering reality: when the National Institutes of Health (NIH) abruptly canceled nearly 2,300 research grants in 2025, women and early-career researchers faced the harshest fallout. These terminated grants, valued at almost $5.1 billion, not only disrupted current research but risked undermining the long-term vitality and diversity of the U.S. biomedical workforce.[PNAS Study]

Notably, these cuts didn’t just halt projects—they magnified existing disparities in funding, advancement, and representation. Now, armed with the first granular analysis of these mass terminations, affected researchers and advocates are turning data into calls for policy reform and grant protections.

Context

In early 2025, following an anti-DEI directive from President Donald Trump, the NIH issued guidance to identify and cut grants related to diversity, equity, and inclusion (DEI), including topics such as transgender issues and Black maternal health. Over just six months (February to mid-August), NIH terminated or froze thousands of federal research grants: 2,291 were canceled altogether, and 1,534 others frozen, representing a combined $5.1 billion in federal research investment with about half ($2.5 billion) still unspent.[Higher Ed Dive]

Analysis of the terminated grants revealed sharp inequities:

• Women researchers led 46% of canceled grants—far higher than their proportion among NIH principal investigators—yet their grants were, on average, smaller (median $940,000 vs. $1.4 million for men) and had more unspent funds at the time of termination (57.9% for women, 48.2% for men), compounding their losses.
• Early-career researchers—assistant professors, graduate students, and postdocs—were also hit hard, often depending on a single grant to maintain their groups, labs, and budding careers.

These abrupt terminations followed significant controversy and legal scrutiny. By August 2025, the Government Accountability Office (GAO) ruled that the administration's actions illegally interrupted congressionally allocated NIH funds, and a federal judge in June ordered NIH to reinstate some affected grants.

Impact

For Women and Early-Career Researchers:

• The sudden loss of grants derailed not just projects, but careers. Women led a disproportionate share of canceled training grants, threatening mentoring pipelines and student opportunities for diverse early-career scientists.
• Early-career researchers, including many assistant professors and postdocs, often relied on a single grant as the foundation of their research programs. Losing this funding mid-project caused stalled publications, job insecurity, and sometimes prompted exits from the field altogether.
• For Black women scientists especially, the terminations sharpened existing inequities. Dr. Jaime Slaughter-Acey, whose $2.4 million grant was canceled, reported immediate setbacks: frozen research, lost data, and an erosion of progress on health equity outcomes.

For the U.S. Biomedical Enterprise:

• The cuts represent a stunning waste of federal investment: 52% of the terminated funds had already been spent on projects now left incomplete or unrecoverable.
• Pipeline effects are severe. According to a STAT News survey, 66% of affected researchers advised trainees to leave academia entirely; 53% recommended seeking opportunities abroad, raising red flags about the retention of U.S. scientific talent.
• Long-term, these disruptions could reduce diversity and innovation—two pillars of a resilient research ecosystem.

For Institutions & Grant Seekers:

• Colleges and universities lost tens of millions in anticipated research support, particularly those already working to address diversity gaps.
• The uncertainties of funding—especially during politically charged cycles—highlight the need for robust grant diversification and crisis contingency planning.

Action

What Grant Seekers Should Do Now:

1. Document and Communicate Impact: If you were affected by NIH terminations, gather records of project disruptions, financial losses, and workforce impacts. This documentation strengthens appeals (for reinstatement or supplemental support) and advocacy efforts.
2. Pursue Supplemental Funding: Watch for NIH and other federal or private re-competition opportunities as some grants may be reinstated or re-bid following legal rulings. Reach out to NIH program officers for current status.
3. Strengthen Collaborations: Build or deepen cross-institutional research partnerships to diversify funding sources and bolster project continuity amid federal uncertainty.
4. Advocate and Share Your Story: Engage with professional societies, advocacy coalitions, or institutional offices to amplify the data and need for funding protections for at-risk groups.
5. Update Grant Strategies: Consider broadening the scope of your funding searches—including state, foundation, or SBIR/STTR opportunities—that may be less vulnerable to sudden federal policy shifts.

Outlook

While the legal process around NIH’s aborted DEI-related terminations is ongoing—with Supreme Court remands and further claims under review—there is growing recognition among funders, universities, and Congress of the need for safeguards that protect equity, continuity, and investment in early-career talent.

Watch for further guidance from the NIH on reinstatement processes, new grant competitions to restore disrupted projects, and institutional efforts to support affected scientists. Continued monitoring and advocacy will be key in the coming months as policies and funding frameworks evolve.

Granted AI helps researchers and nonprofits navigate the changing grant landscape with up-to-date insights and proposal support.